The problem is, many existing therapies for chronic pain are not ideal. Fibromyalgia, for instance, affects up to 3.3% of the population, with less than 10% of patients adhering to treatments after one year. Efficacy and significant side effects have limited the market potential.

As a result, the psychedelic medicine space is experiencing a surge. The medicinal psychedelics market could grow significantly by 2027, eventually becoming a $100 billion market. The psychedelic medical market is in its early days, but the potential of psilocybin is undeniable.

Psilocybin is a psychedelic chemical produced by more than 100 species of mushrooms. Psilocin, which is produced by the body's enzymatic cleavage of psilocybin, interacts with serotonin receptors in the brain, involved in pain processes and the regulation of mood. These receptors are involved in a range of consciousness-altering effects.

Psilocin bound to Serotonin (5-HT2A) Receptor produce a range of consciousness-altering effects. Involved in pain processes and the regulation of mood, these receptors are also involved in the control of anxiety, and cognition. The potential of psychedelic compounds like psilocybin has proven the incredible therapeutic potential of psychedelic medicine for thousands of years. Yet research into their potential has long been hindered by the misperception that they are dangerous substances.

Recently, the FDA designated the psychedelic medicine space as a Breakthrough Therapy. The FDA has proven the incredible therapeutic potential of new substances as a medicine for certain disorders like anxiety, addiction, and cognition.

Although the psychedelic medical market is in its early days, there is a range of rare and difficult to treat diseases that urgently require more effective treatment options. There is a range of rare and difficult to treat diseases that urgently require more effective treatment options. These conditions significantly impact the lives of millions of people, so finding new solutions is critical.

Tryp Therapeutics is an early leader in the psychedelic medicine space with a differentiated value proposition. Tryp Therapeutics is a San Diego-based pharmaceutical company focused on developing psychedelic compounds for treating certain neuropsychiatric disorders. Tryp Therapeutics’ proprietary formulations are based on numerous past studies and the safety profile of its formulations. Tryp Therapeutics intends to directly enter Phase 2A human clinical trials for certain neuropsychiatric disorders. Tryp Therapeutics is an early leader in the psychedelic medicine space with a differentiated value proposition.

Why Invest in Tryp Therapeutics?

- Enhancements in safety and toxicity profiles
- Natural blood-brain barrier penetration
- Enhanced safety and toxicity profiles
- Natural blood-brain barrier penetration

• World class management team with extensive experience with world-class management teams
• Undervalued compared to competitors
• Diversified pipeline of product candidates
• Unique growth platform

Tryp Therapeutics is leading this transformation, leveraging its proprietary formulations. Tryp Therapeutics’ proprietary formulations:

- Focuses on developing psilocybin-based drug therapies for certain neuropsychiatric disorders.
- Enhances safety and toxicity profiles.
- Natural blood-brain barrier penetration.

Psilocybin Work?

HOW DOES PSYLOCYBIN WORK?

Psilocybin is produced in the bodies of millions of people, so finding new solutions is critical. These conditions significantly impact the lives of millions of people, so finding new solutions is critical. These conditions significantly impact the lives of millions of people, so finding new solutions is critical.